Syndax Pharmaceuticals Inc (SNDX)
20.08
-0.58
(-2.81%)
USD |
NASDAQ |
Jul 03, 16:00
Syndax Pharmaceuticals Research and Development Expense (TTM): 185.47M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 185.47M |
| December 31, 2023 | 163.03M |
| September 30, 2023 | 139.75M |
| June 30, 2023 | 127.56M |
| March 31, 2023 | 122.53M |
| December 31, 2022 | 118.50M |
| September 30, 2022 | 110.56M |
| June 30, 2022 | 109.26M |
| March 31, 2022 | 96.40M |
| December 31, 2021 | 88.25M |
| September 30, 2021 | 79.87M |
| June 30, 2021 | 68.67M |
| March 31, 2021 | 62.74M |
| December 31, 2020 | 50.44M |
| September 30, 2020 | 44.42M |
| June 30, 2020 | 39.93M |
| March 31, 2020 | 41.28M |
| December 31, 2019 | 42.99M |
| September 30, 2019 | 49.31M |
| June 30, 2019 | 53.48M |
| March 31, 2019 | 56.04M |
| Date | Value |
|---|---|
| December 31, 2018 | 60.10M |
| September 30, 2018 | 60.88M |
| June 30, 2018 | 58.98M |
| March 31, 2018 | 53.99M |
| December 31, 2017 | 48.20M |
| September 30, 2017 | 40.08M |
| June 30, 2017 | 40.16M |
| March 31, 2017 | 36.43M |
| December 31, 2016 | 31.66M |
| September 30, 2016 | 25.78M |
| June 30, 2016 | 16.47M |
| March 31, 2016 | 12.61M |
| December 31, 2015 | 9.549M |
| September 30, 2015 | 8.417M |
| June 30, 2015 | 7.158M |
| March 31, 2015 | 9.761M |
| December 31, 2014 | 10.18M |
| September 30, 2014 | 9.779M |
| June 30, 2014 | 8.915M |
| March 31, 2014 | 4.772M |
| December 31, 2013 | 3.208M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
39.93M
Minimum
Jun 2020
185.47M
Maximum
Mar 2024
91.63M
Average
88.25M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Agios Pharmaceuticals Inc | 296.84M |
| Krystal Biotech Inc | 45.10M |
| Crinetics Pharmaceuticals Inc | 183.40M |
| Arvinas Inc | 368.80M |
| BridgeBio Pharma Inc | 503.82M |